Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may interfere with the growth of tumor cells by blocking the enzymes
necessary for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who
have metastatic or recurrent colorectal cancer.